JP2018531260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531260A5 JP2018531260A5 JP2018519382A JP2018519382A JP2018531260A5 JP 2018531260 A5 JP2018531260 A5 JP 2018531260A5 JP 2018519382 A JP2018519382 A JP 2018519382A JP 2018519382 A JP2018519382 A JP 2018519382A JP 2018531260 A5 JP2018531260 A5 JP 2018531260A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically engineered
- hematopoietic cell
- human hematopoietic
- engineered human
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 24
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 108091033409 CRISPR Proteins 0.000 claims 5
- 238000010354 CRISPR gene editing Methods 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 3
- 108091092724 Noncoding DNA Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108700010039 chimeric receptor Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022010861A JP7680384B2 (ja) | 2015-10-16 | 2022-01-27 | 系統特異的抗原の阻害のための組成物および方法 |
| JP2024205201A JP2025028963A (ja) | 2015-10-16 | 2024-11-26 | 系統特異的抗原の阻害のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242685P | 2015-10-16 | 2015-10-16 | |
| US62/242,685 | 2015-10-16 | ||
| PCT/US2016/057339 WO2017066760A1 (en) | 2015-10-16 | 2016-10-17 | Compositions and methods for inhibition of lineage specific antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010861A Division JP7680384B2 (ja) | 2015-10-16 | 2022-01-27 | 系統特異的抗原の阻害のための組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531260A JP2018531260A (ja) | 2018-10-25 |
| JP2018531260A6 JP2018531260A6 (ja) | 2018-12-13 |
| JP2018531260A5 true JP2018531260A5 (https=) | 2019-11-28 |
| JP7017506B2 JP7017506B2 (ja) | 2022-02-08 |
Family
ID=58518249
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519382A Active JP7017506B2 (ja) | 2015-10-16 | 2016-10-17 | 系統特異的抗原の阻害のための組成物および方法 |
| JP2022010861A Active JP7680384B2 (ja) | 2015-10-16 | 2022-01-27 | 系統特異的抗原の阻害のための組成物および方法 |
| JP2024205201A Ceased JP2025028963A (ja) | 2015-10-16 | 2024-11-26 | 系統特異的抗原の阻害のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010861A Active JP7680384B2 (ja) | 2015-10-16 | 2022-01-27 | 系統特異的抗原の阻害のための組成物および方法 |
| JP2024205201A Ceased JP2025028963A (ja) | 2015-10-16 | 2024-11-26 | 系統特異的抗原の阻害のための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US10137155B2 (https=) |
| EP (2) | EP4265633A3 (https=) |
| JP (3) | JP7017506B2 (https=) |
| CN (2) | CN108290939B (https=) |
| AU (2) | AU2016337525B2 (https=) |
| CA (1) | CA3001859A1 (https=) |
| ES (1) | ES2962651T3 (https=) |
| IL (3) | IL300420B2 (https=) |
| MX (2) | MX2018004546A (https=) |
| WO (1) | WO2017066760A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| CN108290939B (zh) | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| MY185961A (en) * | 2015-11-04 | 2021-06-14 | Univ Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| SG11201907870VA (en) * | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| KR102320280B1 (ko) * | 2018-05-31 | 2021-11-29 | 주식회사 센트릭스바이오 | CD300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| US20210246472A1 (en) * | 2018-08-21 | 2021-08-12 | Sigma-Aldrich Co. Llc | Down-regulation of the cytosolic dna sensor pathway |
| WO2020051013A2 (en) * | 2018-08-24 | 2020-03-12 | The Trustees Of Columbia University In The City Of New York | Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CN113194966A (zh) * | 2018-10-03 | 2021-07-30 | 柰裴斯生命科学公司 | 抗cd79抗体及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| SG11202104524YA (en) | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| SG11202103832SA (en) * | 2018-11-07 | 2021-05-28 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
| MX2021008490A (es) * | 2019-01-16 | 2021-09-28 | Univ Columbia | Composiciones y metodos para la inhibicion de antigenos con especificidad de linaje. |
| EP3917952A4 (en) * | 2019-01-28 | 2022-11-02 | Multitude Inc. | CD44-SPECIFIC ANTIBODIES |
| CN109777784B (zh) * | 2019-02-22 | 2021-12-31 | 上海尚泰生物技术有限公司 | 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用 |
| CN114423865A (zh) * | 2019-05-23 | 2022-04-29 | Vor生物制药股份有限公司 | Cd33修饰的组合物和方法 |
| CN114401744B (zh) * | 2019-06-26 | 2024-11-05 | 纪念斯隆凯特琳癌症中心 | 用于治疗癌症的抗cd33抗体 |
| AU2020336211A1 (en) * | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CD123 modification |
| US20220290160A1 (en) * | 2019-08-28 | 2022-09-15 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| WO2021081244A1 (en) * | 2019-10-22 | 2021-04-29 | Fred Hutchinson Cancer Research Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
| WO2022250433A1 (ko) * | 2021-05-24 | 2022-12-01 | 주식회사 센트릭스바이오 | Cd300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 |
| WO2021188590A2 (en) * | 2020-03-16 | 2021-09-23 | Magenta Therapeutics, Inc. | T-cell bispecific binding proteins |
| CN116157135A (zh) * | 2020-06-03 | 2023-05-23 | 纽约市哥伦比亚大学理事会 | 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法 |
| US20240110189A1 (en) | 2020-08-28 | 2024-04-04 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| US20240238344A1 (en) | 2020-08-28 | 2024-07-18 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| JP2023541457A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| WO2022056490A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
| WO2022056459A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd5 modification |
| WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| US20230364146A1 (en) | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| JP2023550355A (ja) * | 2020-11-13 | 2023-12-01 | ブイオーアール バイオファーマ インコーポレーテッド | キメラ抗原受容体を発現する遺伝子操作された細胞に関連する方法および組成物 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022147347A1 (en) | 2020-12-31 | 2022-07-07 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| CN115443333B (zh) * | 2021-04-27 | 2025-04-25 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| AU2022280586B2 (en) * | 2021-05-24 | 2024-10-31 | CentricsBio, Inc. | Chimeric antigen receptor specifically binding to cd300c antigen or receptor thereof |
| US20240384304A1 (en) | 2021-07-06 | 2024-11-21 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| US20250082755A1 (en) | 2021-07-29 | 2025-03-13 | Vor Biopharma Inc. | Chimeric antigen receptors for treatment of cancer |
| AU2022324093A1 (en) | 2021-08-02 | 2024-02-08 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| CA3232593A1 (en) * | 2021-09-14 | 2023-03-23 | Vor Biopharma Inc. | Compositions and methods for multiplex base editing in hematopoietic cells |
| CA3236152A1 (en) | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| US20250295695A1 (en) | 2022-04-04 | 2025-09-25 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
| EP4507794A1 (en) | 2022-04-11 | 2025-02-19 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
| CN114778857B (zh) * | 2022-06-17 | 2022-08-23 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 检测非造血系统肿瘤的试剂组合物及其应用 |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| WO2024168312A1 (en) | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
| WO2024238565A1 (en) | 2023-05-15 | 2024-11-21 | Vor Biopharma Inc. | Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| CN117946270B (zh) * | 2023-12-26 | 2025-02-11 | 华润生物医药有限公司 | 抗cd93抗体及其用途 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
| JP4041535B2 (ja) | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| WO1993025216A1 (en) * | 1992-06-08 | 1993-12-23 | Becton, Dickinson And Company | Human primitive stem cells |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5756910A (en) | 1996-08-28 | 1998-05-26 | Burgett, Inc. | Method and apparatus for actuating solenoids in a player piano |
| ES2278399T3 (es) | 1996-11-20 | 2007-08-01 | Introgen Therapeutics, Inc. | Metodo mejorado para la produccion y purificacion de vectores adenovirales. |
| JP2010515464A (ja) | 2007-01-11 | 2010-05-13 | イエール・ユニバーシテイ | Ｈｉｖ細胞表面受容体の標的化不活性化のための組成物および方法 |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| CH704227B1 (fr) | 2009-10-19 | 2015-05-15 | Tristem Trading Cyprus Ltd | Procédé pour obtenir des cellules cibles reprogrammées. |
| CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| EP2906684B8 (en) | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| TW201446794A (zh) | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| US10287354B2 (en) * | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| EP3126390B2 (en) * | 2014-04-03 | 2026-01-07 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| EP3134515B1 (en) | 2014-04-24 | 2019-03-27 | Board of Regents, The University of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| SG10201913765YA (en) * | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| US10201606B2 (en) * | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| WO2016176651A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| AU2016261358B2 (en) * | 2015-05-11 | 2021-09-16 | Editas Medicine, Inc. | Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells |
| CN108290939B (zh) * | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| MY185961A (en) | 2015-11-04 | 2021-06-14 | Univ Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| AU2017355218B2 (en) | 2016-11-02 | 2024-02-22 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
-
2016
- 2016-10-17 CN CN201680067189.3A patent/CN108290939B/zh active Active
- 2016-10-17 EP EP23187118.7A patent/EP4265633A3/en active Pending
- 2016-10-17 IL IL300420A patent/IL300420B2/en unknown
- 2016-10-17 CA CA3001859A patent/CA3001859A1/en active Pending
- 2016-10-17 AU AU2016337525A patent/AU2016337525B2/en active Active
- 2016-10-17 MX MX2018004546A patent/MX2018004546A/es unknown
- 2016-10-17 CN CN202211723888.2A patent/CN116712535A/zh active Pending
- 2016-10-17 JP JP2018519382A patent/JP7017506B2/ja active Active
- 2016-10-17 IL IL258491A patent/IL258491B2/en unknown
- 2016-10-17 EP EP16856410.2A patent/EP3362472B1/en active Active
- 2016-10-17 WO PCT/US2016/057339 patent/WO2017066760A1/en not_active Ceased
- 2016-10-17 ES ES16856410T patent/ES2962651T3/es active Active
-
2017
- 2017-07-20 US US15/655,432 patent/US10137155B2/en active Active
-
2018
- 2018-04-12 MX MX2024000739A patent/MX2024000739A/es unknown
- 2018-10-29 US US16/174,089 patent/US10660919B2/en active Active
- 2018-10-29 US US16/174,005 patent/US10786535B2/en active Active
-
2019
- 2019-06-25 US US16/451,934 patent/US10668103B2/en active Active
- 2019-06-25 US US16/451,906 patent/US20190314418A1/en active Pending
-
2020
- 2020-05-19 US US16/877,932 patent/US10912799B2/en active Active
-
2021
- 2021-04-29 US US17/243,987 patent/US20210252073A1/en active Pending
- 2021-12-15 IL IL289046A patent/IL289046A/en unknown
- 2021-12-23 AU AU2021290320A patent/AU2021290320A1/en not_active Abandoned
-
2022
- 2022-01-27 JP JP2022010861A patent/JP7680384B2/ja active Active
-
2024
- 2024-11-26 JP JP2024205201A patent/JP2025028963A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531260A5 (https=) | ||
| Zhu et al. | Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity | |
| JP7168641B2 (ja) | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 | |
| Tsao et al. | CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis | |
| Ruggeri et al. | Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells | |
| Battella et al. | Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions | |
| HUS2200044I1 (hu) | Humanizált anti-CD19 ellenanyagok és használatuk daganatokban, transzplantációknál és autoimmun betegségekben | |
| PH12017501732A1 (en) | Therapeutic antibodies and their uses | |
| JP2018510881A5 (https=) | ||
| JOP20190116A1 (ar) | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها | |
| PH12021551484A1 (en) | Antibodies binding to cd3 | |
| HRP20171577T1 (hr) | Uporaba t stanica modificiranih himernim receptorom za antigen za liječenje karcinoma | |
| EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| JP2018508215A5 (https=) | ||
| MY187624A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor | |
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| AU2019277660A1 (en) | Materials and methods for treating cancer | |
| Bugide et al. | Epigenetic mechanisms dictating eradication of cancer by natural killer cells | |
| PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
| CN113194715A (zh) | 用于治疗癌症的材料和方法 | |
| MX2023009211A (es) | Anticuerpos biespecificos con pares de carga y usos de los mismos. | |
| Balduzzi et al. | Acute lymphoblastic leukaemia in the youngest: haematopoietic stem cell transplantation and beyond | |
| Chen et al. | Stereotactic ablative radiotherapy and FAPα-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer | |
| Masu et al. | Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression |